Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To evaluate the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (PA-HAIC) plus programmed death-1 (PD-1) inhibitors versus PA-HAIC alone for hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI).
Methods: This retrospective study included HCC patients with MVI who were treated with either PA-HAIC or PA-HAIC plus PD-1 inhibitors between February 2021 and February 2024. The differences in baseline characteristics, disease-free survival (DFS), and overall survival (OS) were compared between the two groups before and after propensity score-matching (PSM). The treatment-related adverse events (TRAEs) were compared among the two groups after PSM. Cox regression analysis was utilized to determine factors affecting DFS and OS.
Results: A total of 102 patients were included in the study: 65 in the PA-HAIC group and 37 in the PA-HAIC plus PD-1 group. PSM analysis generated 32 matched pairs of patients in the two groups. The HCC patients in the PA-HAIC plus PD-1 group experienced significantly better DFS compared to those in the PA-HAIC group alone (HR: 0.412; P = 0.031). However, there was no significant difference in OS between the two groups (P = 0.124). Multivariate analysis identified the treatment option (PA-HAIC vs. PA-HAIC + PD-1) as an independent predictive factor for DFS of the patients. Furthermore, the results indicated no statistically significant difference in the incidence of TRAEs between the two groups (P < 0.05).
Conclusion: In comparison with PA-HAIC alone, PA-HAIC combined with PD-1 inhibitors could improve the DFS benefits with acceptable safety profiles in HCC patients with MVI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887270 | PMC |
| http://dx.doi.org/10.1186/s12885-025-13793-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Significance of Circulating Tumor Cells in the Portal Vein of Patients with Hepatocellular Carcinoma Undergoing Anatomical Liver Resection.
Ann Surg Oncol
September 2025
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Background: Hepatocellular carcinoma (HCC) frequently invades the portal vein, leading to early recurrence and a poor prognosis. However, the mechanisms underlying this invasion remain unclear. In this study, we aimed to detect portal vein circulating tumor cells (CTCs) using a Glypican-3-positive detection method and evaluate their prognostic significance.
View Article and Find Full Text PDFExosomal Proteome from Hepatocellular Carcinoma Patient-Derived Xenograft Mice Serves as Identity of Liver Cancer.
J Proteome Res
September 2025
State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Institute of Lifeomics, Beijing 102206, China.
Hepatocellular carcinoma (HCC) constitutes approximately 90% of liver cancers, yet its early detection remains challenging due to the low sensitivity of current diagnostic methods and the difficulty in identifying minimal cancer cells within the body. This study employed a patient-derived xenograft (PDX) mouse model to screen for biomarkers, leveraging its advantage of low background interference compared to human serum exosome studies. Using a novel microextraction technique, exosomes were isolated from just one microliter of serum from HCC PDX mice, followed by proteomic profiling.
View Article and Find Full Text PDFBackground: Since 2013, we have performed conversion surgery after hepatic arterial infusion chemotherapy (HAIC) for initially unresectable locally advanced hepatocellular carcinoma (LA-HCC).
Methods: Between 2013 and 2021, we assessed the surgical and oncological outcomes and pathological findings of patients with LA-HCC without extrahepatic spread (EHS) whose tumors converted from unresectable to resectable status with the New-FP regimen HAIC.
Results: We censored 153 patients with LA-HCC (Child-Pugh A, without EHS) indicated for HAIC.
FIB-3 index as a novel age-independent predictor of liver fibrosis and prognosis in hepatocellular carcinoma patients undergoing hepatectomy.
Ann Gastroenterol Surg
September 2025
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima University Hiroshima Japan.
Background: Liver fibrosis is a key factor in the progression of chronic liver diseases, including viral hepatitis and metabolic dysfunction-associated steatotic liver disease. If untreated, fibrosis can progress to cirrhosis, increasing the risk of liver cancer or failure. This study evaluates the Fibrosis (FIB)-3 index, a novel marker free from age-related biases, for predicting liver fibrosis and 5-year outcomes in hepatocellular carcinoma (HCC) patients undergoing hepatectomy.
View Article and Find Full Text PDFPrediction of Hepatocellular Carcinoma and Other Liver-Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction-Associated Steatotic Liver Disease.
Aliment Pharmacol Ther
September 2025
Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands.
Introduction: Metabolic dysfunction and metabolic dysfunction-associated steatotic liver disease (MASLD) are associated with an increased risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to study risk factors for HCC and to assess the performance of the PAGE-B score in this population.
Methods: We included CHB patients with ≥ 1 metabolic comorbidity from nine centres.